Patent expiry dates for best-selling biologicals

GaBI Journal

Volumn 4, Issue 4, 2015, Pages 178-179

  Derbyshire, Michelle ^a  

^a NONE

Author keywords

Biological; Biosimilar; Patent

Indexed keywords

ANTIANEMIC AGENT; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; INSULIN; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; ASIA; BIOTECHNOLOGY; BUDGET; COMMERCIAL PHENOMENA; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; DRUG USE; EUROPE; EUROPEAN UNION; GOVERNMENT REGULATION; HEALTH CARE COST; PATENT; SHELF LIFE; SOUTH AND CENTRAL AMERICA; UNITED STATES;

EID: 85008258251     PISSN: 20336403     EISSN: 20336772     Source Type: Journal    
DOI: 10.5639/gabij.2015.0404.040     Document Type: Article

References (1)

1. GaBI Online-Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Nov 19]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe